Our findings suggest that high-risk score gliomas may drive an immunosuppressive microenvironment via the CSF1R-macrophage axis, thereby restricting the anti-tumor functionality of CD8+ T cells and, ultimately, leading to resistance to ICB therapy. Here, CSF1R is linked to glioma.